ClinicalTrials.gov (NCT01581060) Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours. U.S. National Institutes of Health.
Ref 544302
MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.